About
SenzaGen develops in vitro genomic-based assays and services for predicting chemical and cosmetic allergy and immunotoxicity, using its GARD (Genomic Allergen Rapid Detection) technology to provide non-animal testing solutions.
Explore SenzaGen's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.